Explore "The Ozempic Revolution" by Dr Alexandra Sowa—a guide to weight-loss drugs like Ozempic, their benefits, side effects ...

After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead. Yet another ...

Novo Nordisk A/S (NYSE: NVO) is one of the high-margin pharma stocks to buy now. Berenberg has reaffirmed its Hold rating on ...

The sale represents Clever Culture’s fifth engagement with a leading pharma manufacturer, including AstraZeneca, Bristol Myers Squibb and Thermo Fisher. The company is due to report its Q4 FY25 ...

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

Dr. Xie Fangmin remarked, "We are partnering with Novo Nordisk, a leading global healthcare company, to explore AI technology and address the pain points of traditional health management. Together, we ...

Biochemist Svetlana Mojsov, honored for GLP-1 research that has transformed metabolic disease care, says she’s grateful to ...

In advance of CMS’ negotiated price for the blood thinner taking effect next year, partners Bristol Myers Squibb and Pfizer ...

Taking a page from Eli Lilly and Novo Nordisk, who have launched online programs to sell their diabetes and obesity drugs ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...